BEAM icon

Beam Therapeutics

29.01 USD
+2.16
8.04%
At close Dec 20, 4:00 PM EST
After hours
29.03
+0.02
0.07%
1 day
8.04%
5 days
3.28%
1 month
18.46%
3 months
13.10%
6 months
25.91%
Year to date
5.84%
1 year
4.99%
5 years
54.72%
10 years
54.72%
 

About: Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.

Employees: 374

0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 4 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

94% more call options, than puts

Call options by funds: $12.1M | Put options by funds: $6.22M

50% more funds holding in top 10

Funds holding in top 10: 2 [Q2] → 3 (+1) [Q3]

27% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 22

5% more capital invested

Capital invested by funds: $1.84B [Q2] → $1.93B (+$97.5M) [Q3]

3% more funds holding

Funds holding: 213 [Q2] → 219 (+6) [Q3]

7% more repeat investments, than reductions

Existing positions increased: 72 | Existing positions reduced: 67

0.63% more ownership

Funds ownership: 95.21% [Q2] → 95.84% (+0.63%) [Q3]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$24
17%
downside
Avg. target
$42
44%
upside
High target
$80
176%
upside

4 analyst ratings

positive
50%
neutral
50%
negative
0%
HC Wainwright & Co.
Patrick Trucchio
30% 1-year accuracy
47 / 158 met price target
176%upside
$80
Buy
Reiterated
9 Dec 2024
RBC Capital
Luca Issi
27% 1-year accuracy
15 / 56 met price target
17%downside
$24
Sector Perform
Maintained
6 Nov 2024
Leerink Partners
Rick Bienkowski
29% 1-year accuracy
2 / 7 met price target
34%upside
$39
Outperform
Upgraded
6 Nov 2024
Scotiabank
Greg Harrison
33% 1-year accuracy
9 / 27 met price target
17%downside
$24
Sector Perform
Initiated
16 Oct 2024

Financial journalist opinion

Based on 6 articles about BEAM published over the past 30 days

Positive
Zacks Investment Research
1 week ago
Beam Therapeutics Appoints Sravan Emany as New CFO, Shares Up
BEAM appoints Sravan K. Emany as its new chief financial officer, effective Dec. 19.
Beam Therapeutics Appoints Sravan Emany as New CFO, Shares Up
Neutral
GlobeNewsWire
1 week ago
Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting
NHP Data Showed CD117 Monoclonal Antibody (mAb) Conditioning Successfully Achieved Long-term Engraftment of Base-edited Hematopoietic Stem Cells and Induced Robust Levels of  Hemoglobin F
Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting
Neutral
GlobeNewsWire
2 weeks ago
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting
All Seven Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting
Neutral
GlobeNewsWire
2 weeks ago
Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer
CAMBRIDGE, Mass., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Sravan K. Emany as chief financial officer (CFO), effective December 19, 2024. Mr. Emany brings to Beam a breadth of global operational, commercial and financial experience with multinational public corporations and financial institutions. He most recently served as CFO and chief operating officer at Ironwood Pharmaceuticals, Inc.
Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer
Negative
Zacks Investment Research
2 weeks ago
Why Is Beam Therapeutics (BEAM) Down 2.3% Since Last Earnings Report?
Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock?
Why Is Beam Therapeutics (BEAM) Down 2.3% Since Last Earnings Report?
Neutral
GlobeNewsWire
2 weeks ago
Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader
CAMBRIDGE, Mass., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Chirfi Guindo, chief marketing officer of Human Health at Merck & Co., Inc., to its board of directors. Mr. Guindo is a seasoned executive in the pharmaceutical industry and has been a key leader at Merck for more than 25 years, where he held senior executive roles spanning global strategy, commercial operations and leadership in healthcare solutions.
Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader
Neutral
GlobeNewsWire
1 month ago
Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference
CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer of Beam, plans to participate in a fireside chat during the 2024 Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 10:00 a.m. GMT in London.
Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference
Neutral
Seeking Alpha
1 month ago
Beam Therapeutics: Additional BEAM-101 And ESCAPE Tech Data At ASH 2024 Makes This A Watch
Beam Therapeutics Inc. will present additional data from phase 1/2 BEACON study, using BEAM-101 for the treatment of patients with SCD at the upcoming ASH Annual Meeting on December 7th - 10th of 2024. ESCAPE technology, looking to provide non-genotoxic conditioning for HSCT patients, is to be presented at the upcoming ASH 2024 Annual Meeting. The global Sickle Cell Disease treatment market size is projected to grow to $9.84 billion by 2030.
Beam Therapeutics: Additional BEAM-101 And ESCAPE Tech Data At ASH 2024 Makes This A Watch
Negative
Zacks Investment Research
1 month ago
Beam Therapeutics' Q3 Earnings & Revenues Fall Shy of Estimates
BEAM's third-quarter 2024 earnings and revenues miss estimates. The company remains focused on pipeline development.
Beam Therapeutics' Q3 Earnings & Revenues Fall Shy of Estimates
Neutral
Seeking Alpha
1 month ago
Beam Therapeutics Inc. (BEAM) Q3 2024 Earnings Call Transcript
Beam Therapeutics Inc (NASDAQ:BEAM ) Q3 2024 Earnings Conference Call November 5, 2024 8:30 AM ET Company Participants Holly Manning - Vice President of Investor Relations & External Communications John Evans - Chief Executive Officer Giuseppe Ciaramella - President Amy Simon - Chief Medical Officer Conference Call Participants Gena Wang - Barclays Dae Gon Ha - Stifel Eric Joseph - JPMorgan Kostas Biliouris - BMO Capital Markets Samantha Semenkow - Citi Sami Corwin - William Blair Luca Issi - RBC Capital Michael Yee - Jefferies Rick Bienkowski - Cantor Fitzgerald Mani Foroohar - Leerink Partners Operator Good morning, and welcome to the Beam Therapeutics Conference Call. At this time, all participants are in a listen-only mode.
Beam Therapeutics Inc. (BEAM) Q3 2024 Earnings Call Transcript
Charts implemented using Lightweight Charts™